Drug intelligence / Profile preview

ND1.1

Development stage: Phase 1
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Direct Ileal Administration (as Per Clinical Trial)[3]

Overview

ND1.1 is an adjuvanted adenoviral-based avian influenza vaccine candidate that has been studied for its immunogenicity and safety when delivered directly to the ileum in humans[3]. It is designed as a gene therapy or vaccine platform using an adenoviral vector, with the goal of inducing immune responses against avian influenza antigens.

Brand names: ND1.1ND-1.1ND 1.1
Other names: ND1.1ND-1.1ND 1.1

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on ND1.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND1.1.

Explore the full profile